ERAS

Erasca is a clinical-stage precision oncology company focused on discovering and developing therapies for RAS/MAPK pathway-driven cancers through small molecule and large molecule modalities. The company's pipeline includes two clinical-stage programs: ERAS-0015, a pan-RAS molecular glue, and ERAS-4001, a pan-KRAS inhibitor, along with ERAS-12, a discovery-stage program comprising an EGFR D2/D3 biparatopic antibody with an identified lead candidate. Erasca pursues three therapeutic strategies targeting upstream and downstream MAPK pathway nodes, RAS directly, and escape routes that emerge in response to treatment.

Pipeline

Catalyst Calendar